433 related articles for article (PubMed ID: 23278775)
1. Efficacy of the 6-month thrice-weekly regimen in the treatment of new sputum smear-positive pulmonary tuberculosis under clinical trial conditions.
Banu Rekha VV; Rajaram K; Kripasankar AS; Parthasarathy R; Umapathy KC; Sheikh I; Selvakumar N; Victor M; Niruparani C; Sridhar R; Jawahar MS
Natl Med J India; 2012; 25(4):196-200. PubMed ID: 23278775
[TBL] [Abstract][Full Text] [Related]
2. Long term follow up of HIV-infected patients with tuberculosis treated with 6-month intermittent short course chemotherapy.
Swaminathan S; Deivanayagam CN; Rajasekaran S; Venkatesan P; Padmapriyadarsini C; Menon PA; Ponnuraja C; Dilip M
Natl Med J India; 2008; 21(1):3-8. PubMed ID: 18472696
[TBL] [Abstract][Full Text] [Related]
3. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
4. A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Tuberculosis Research Centre.
Int J Tuberc Lung Dis; 1997 Dec; 1(6):509-17. PubMed ID: 9487448
[TBL] [Abstract][Full Text] [Related]
5. Split-drug regimens for the treatment of patients with sputum smear-positive pulmonary tuberculosis--a unique approach.
Santha T; Rehman F; Mitchison DA; Sarma GR; Reetha AM; Prabhaker R;
Trop Med Int Health; 2004 May; 9(5):551-8. PubMed ID: 15117298
[TBL] [Abstract][Full Text] [Related]
6. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
7. [Results of a therapeutic trial comparing a 6-month regimen to a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Final report: results 3 years after the onset of treatment].
Berkani M; Chaulet P; Darbyshire JH; Nunn A; Fox W
Rev Mal Respir; 1986; 3(2):73-85. PubMed ID: 3726263
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a non-rifampicin continuation phase (6HE) following thrice-weekly intensive phase for the treatment of new sputum positive pulmonary tuberculosis.
Indian J Tuberc; 2007 Apr; 54(2):84-90. PubMed ID: 17575680
[TBL] [Abstract][Full Text] [Related]
9. Treatment of lymph node tuberculosis--a randomized clinical trial of two 6-month regimens.
Jawahar MS; Rajaram K; Sivasubramanian S; Paramasivan CN; Chandrasekar K; Kamaludeen MN; Thirithuvathas AJ; Ananthalakshmi V; Prabhakar R
Trop Med Int Health; 2005 Nov; 10(11):1090-8. PubMed ID: 16262733
[TBL] [Abstract][Full Text] [Related]
10. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
Bwire R; Borgdorff MW; Sticht-Groh V; Rieder HL; Kawuma HJ; Bretzel G; Rüsch-Gerdes S
East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.
Swaminathan S; Narendran G; Venkatesan P; Iliayas S; Santhanakrishnan R; Menon PA; Padmapriyadarsini C; Ramachandran R; Chinnaiyan P; Suhadev M; Sakthivel R; Narayanan PR
Am J Respir Crit Care Med; 2010 Apr; 181(7):743-51. PubMed ID: 19965813
[TBL] [Abstract][Full Text] [Related]
12. Factors influencing time to smear conversion in patients with smear-positive pulmonary tuberculosis.
Wang JY; Lee LN; Yu CJ; Chien YJ; Yang PC;
Respirology; 2009 Sep; 14(7):1012-9. PubMed ID: 19659516
[TBL] [Abstract][Full Text] [Related]
13. Modified short-course chemotherapy of pulmonary tuberculosis in Ibadan, Nigeria--a preliminary report.
Ige OM; Bakare NA; Onadeko BO
Afr J Med Med Sci; 2000 Mar; 29(1):51-3. PubMed ID: 11379469
[TBL] [Abstract][Full Text] [Related]
14. Sputum culture conversion with moxifloxacin-containing regimens in the treatment of patients with newly diagnosed sputum-positive pulmonary tuberculosis in South India.
Velayutham BV; Allaudeen IS; Sivaramakrishnan GN; Perumal V; Nair D; Chinnaiyan P; Paramasivam PK; Dhanaraj B; Santhanakrishnan RK; Navaneethapandian GP; Marimuthu MK; Kumar V; Kandasamy C; Dharuman K; Elangovan T; Narasimhan M; Rathinam S; Vadivelu G; Rathinam P; Chockalingam C; Jayabal L; Swaminathan S; Shaheed JM
Clin Infect Dis; 2014 Nov; 59(10):e142-9. PubMed ID: 25028463
[TBL] [Abstract][Full Text] [Related]
15. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
Nolan CM; Goldberg SV
Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
[TBL] [Abstract][Full Text] [Related]
16. Should we take a history of prior treatment, and check sputum status at 2-3 months when treating patients for tuberculosis?
Wilkinson D; Bechan S; Connolly C; Standing E; Short GM
Int J Tuberc Lung Dis; 1998 Jan; 2(1):52-5. PubMed ID: 9562111
[TBL] [Abstract][Full Text] [Related]
17. A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. British Thoracic Society.
Br J Dis Chest; 1984 Oct; 78(4):330-6. PubMed ID: 6386028
[TBL] [Abstract][Full Text] [Related]
18. Study of drug resistance in previously treated tuberculosis patients in Gujarat, India.
Shah AR; Agarwal SK; Shah KV
Int J Tuberc Lung Dis; 2002 Dec; 6(12):1098-101. PubMed ID: 12546118
[TBL] [Abstract][Full Text] [Related]
19. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures.
Tam CM; Chan SL; Kam KM; Goodall RL; Mitchison DA
Int J Tuberc Lung Dis; 2002 Jan; 6(1):3-10. PubMed ID: 11931398
[TBL] [Abstract][Full Text] [Related]
20. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
